IFM Investors Pty Ltd Has $3.83 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

IFM Investors Pty Ltd grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 25,651 shares of the biopharmaceutical company’s stock after acquiring an additional 780 shares during the period. IFM Investors Pty Ltd’s holdings in Alnylam Pharmaceuticals were worth $3,834,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Allspring Global Investments Holdings LLC boosted its holdings in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares during the last quarter. Quent Capital LLC lifted its position in shares of Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 123 shares during the period. Anchor Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $38,000. GAMMA Investing LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $52,000. Finally, V Square Quantitative Management LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $52,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of recent analyst reports. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 13th. Wolfe Research began coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. Wells Fargo & Company dropped their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research report on Friday, February 16th. Needham & Company LLC restated a “buy” rating and issued a $200.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, April 21st. Eight equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $215.88.

Alnylam Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ:ALNY traded down $0.40 during mid-day trading on Friday, hitting $143.31. 479,139 shares of the company traded hands, compared to its average volume of 467,891. The stock has a market cap of $18.05 billion, a P/E ratio of -40.26 and a beta of 0.39. The stock has a 50-day moving average price of $150.21 and a two-hundred day moving average price of $165.79. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. During the same quarter in the previous year, the company earned ($1.68) EPS. The business’s revenue was up 31.2% compared to the same quarter last year. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.